Skip to main content
OpenTrials

Clinical trial condition

Relapsed or Refractory Multiple Myeloma

Explore clinical trials studying Relapsed or Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

44 public trials 13 recruiting studies
Refine in advanced search Browse all conditions

Relapsed or Refractory Multiple Myeloma trial results

Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07116616

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of Alabama at Birmingham Hospital Birmingham, Alabama, United States
  • UCSF San Francisco, California, United States
  • Emory University Hospital Atlanta, Georgia, United States
  • Mass General Brigham Boston, Massachusetts, United States
View Trial Details
Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Local Institution - 0366 Los Alamitos, California, United States
  • Local Institution - 0272 San Diego, California, United States
  • Local Institution - 0273 West Hollywood, California, United States
  • Local Institution - 0381 Aurora, Colorado, United States
View all 266 locations
View Trial Details
Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335

Conditions
Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +22 more
Locations
  • City of Hope Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 29 locations
View Trial Details
Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT05927571

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • Calvary Mater Newcastle Waratah, New South Wales, Australia
  • Royal Adelaide Hospital;Haematology Clinical Trials Unit Adelaide, South Australia, Australia
  • St. Vincent's Hospital Melbourne Melbourne, Victoria, Australia
View all 14 locations
View Trial Details
Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

NCT06375044

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Mayo Clinic Florida Jacksonville, Florida, United States
  • Dana Farber Cancer institution Boston, Massachusetts, United States
  • Mayo Clinic Rochester Rochester, Minnesota, United States
View Trial Details
Recruiting

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06574568

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Beijing Chao-yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Jishuitan Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Shunde Hospital of Southern Medical University Foshan, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View Trial Details

Related conditions